Company Filing History:
8 out of 12,164 
4 out of 540 
1 out of 504 Years Active: 1978-1998
Title: The Innovations of Eugen Schnabel
Introduction
Eugen Schnabel is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of peptides with therapeutic applications. With a total of 13 patents to his name, Schnabel's work has had a profound impact on medical science.
Latest Patents
Schnabel's latest patents focus on variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology. These peptides, which have sequences similar to bovine pancreatic trypsin inhibitor (aprotinin), involve modifications at specific amino acid positions. The innovations aim to create therapeutic agents for diseases associated with excessive proteinases. His work emphasizes the pharmaceutical use of these peptides, showcasing their potential in treating various medical conditions.
Career Highlights
Throughout his career, Schnabel has worked with prominent companies such as Bayer Aktiengesellschaft and Miles Inc. His experience in these organizations has allowed him to refine his expertise in biochemistry and patent development. His contributions have been instrumental in advancing the understanding and application of recombinant DNA technology in medicine.
Collaborations
Schnabel has collaborated with notable colleagues, including Gerd Reinhardt and Ernst-August Auerswald. These partnerships have fostered a collaborative environment that has led to innovative breakthroughs in their respective fields.
Conclusion
Eugen Schnabel's work exemplifies the intersection of innovation and medical science. His patents and collaborations highlight his commitment to advancing therapeutic solutions through biochemistry. His contributions continue to influence the field and pave the way for future discoveries.